HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 278, Issue 35, 32914-32920, August 29, 2003

This Article Abstract Full Text (PDF) All Versions of this Article: 278/35/32914    most recent M302444200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoon, S.-W. Articles by Poo, H. Search for Related Content PubMed PubMed Citation Articles by Yoon, S.-W. Articles by Poo, H. Social Bookmarking                      What's this?

-Melanocyte-stimulating Hormone Inhibits Lipopolysaccharide-induced Tumor Necrosis Factor- Production in Leukocytes by Modulating Protein Kinase A, p38 Kinase, and Nuclear Factor B Signaling Pathways^*

Sun-Woo Yoon , Sung-Ho Goh , Jang-Soo Chun , Eun-Wie Cho , Myung-Kyu Lee , Kil-Lyong Kim ¶, Jae-Jin Kim ||, Chul-Joong Kim ** and Haryoung Poo  

From the Proteome Research Lab, Korea Research Institute of Bioscience and Biotechnology, Daejon 305-600, the Department of Life Science, Kwangju Institute of Science and Technology, Gwangju 500-712, the ^¶Department of Biological Science, Sungkyunkwan University, Suwon 440-746, the ^||Department of Biology, PaiChai University, Daejon 302-735, and the ^**Department of Veterinary Medicine, Choongnam National University, Daejon 305-764, Korea

Received for publication, March 10, 2003 , and in revised form, May 27, 2003.

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
The neuropeptide -melanocyte-stimulating hormone (-MSH) inhibits inflammation by down-regulating the expression of proinflammatory cytokines such as tumor necrosis factor- (TNF-) in leukocytes via stimulation of -MSH cell surface receptors. However, the signaling mechanism of -MSH action has not yet been clearly elucidated. Here, we have investigated signaling pathways by which -MSH inhibits lipopolysaccharide (LPS)-induced TNF- production in leukocytes such as THP-1 cells. We focused on the possible roles of protein kinase A (PKA), p38 kinase, and nuclear factor B (NFB) signaling. In THP-1 cells, LPS is known to activate p38 kinase, which in turn activates NFB to induce TNF- production. We found that pretreatment of cells with -MSH blocked LPS-induced p38 kinase and NFB activation as well as TNF- production. This response was proportional to -MSH receptor expression levels, and addition of an -MSH receptor antagonist abolished the inhibitory effects. In addition, -MSH treatment activated PKA, and PKA inhibition abrogated the inhibitory effects of -MSH on p38 kinase activation, NFB activation, and TNF- production. Taken together, our results indicate that stimulation of PKA by -MSH causes inhibition of LPS-induced activation of p38 kinase and NFB to block TNF- production.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
The -melanocyte-stimulating hormone (-MSH)¹ is a 13-amino-acid-long neuropeptide produced by intracellular cleavage of the proopiomelanocortin hormone. -MSH mediates the communication between the nervous and immune systems (1, 2) and is expressed in pituitary cells, neurons, keratinocytes, and macrophages, where it regulates neurological, endocrine, and immune activities (1, 3–6). The anti-inflammatory activity of -MSH has been demonstrated in various disease models including arthritis, septic shock induced by hepatic injury, and endotoxemia/ischemia, suggesting that -MSH is a promising candidate therapeutic drug for inflammatory diseases (7–10). The anti-inflammatory effects of -MSH involve a reduction in expression of inflammatory cytokines, including tumor necrosis factor (TNF)-, interferon-, and interleukin-1, -6, and -8, and inhibition of the inflammatory actions of leukocytes such as neutrophils and macrophages (9, 11–13). In addition, it has been shown that the anti-inflammatory action of -MSH is due to its ability to block proinflammatory signaling such as activation of nuclear factor B (NFB) (13, 14). -MSH exerts its cellular effects by binding to five different G protein-coupled receptors called melanocortin receptors (MC₁R_{_} MC₅R) (15–18). Ligand binding to MCRs activates adenyl cyclase, which leads to the production of cAMP and subsequent activation of protein kinase A (PKA) (15, 19, 20). MC₁R, which is expressed on the surface of leukocytes, is thought to be the major receptor mediating the anti-inflammatory activity of -MSH (19, 20). However, the molecular mechanism of intracellular signal transduction leading to the anti-inflammatory action of -MSH is not yet clearly understood.

Lipopolysaccharide (LPS) is a major inflammatory molecule that triggers the production of proinflammatory cytokines such as TNF- in various cell types (21, 22). In monocytes and macrophages, LPS is known to stimulate TNF- production by activating mitogen-activated protein (MAP) kinase subtypes including extracellular signal-regulated kinase (ERK), p38 kinase, and c-Jun N-terminal kinase (23–25). Among the MAP kinase subtypes, specific inhibitors for p38 kinase have been shown to inhibit LPS-induced TNF- production (26–28). In addition, -MSH is known to block LPS-induced expression of TNF- (19), and the inhibitory effects of -MSH are mediated by the inhibition of NFB, which stimulates TNF- production at the transcriptional level (29, 30).

Although the signaling pathway by which -MSH blocks TNF- production is not clearly understood, the above observations suggest the possibility that -MSH blocks LPS-induced TNF- production by modulating MAP kinase and NFB activation. Accordingly, we have investigated the functional relationships among PKA, p38 kinase, and NFB in the antiinflammatory action of -MSH within inflammatory leukocytes (i.e. macrophages and neutrophils). For this purpose, we treated THP-1 and HL-60 cells with phorbol myristate acetate (PMA) or Me₂SO, which induces differentiation into macrophages and neutrophils, respectively. Using these cells, we found that activation of PKA by -MSH inhibits LPS-induced TNF- production in differentiated THP-1 cells by inhibiting LPS-induced activation of p38 kinase and subsequent NFB activation to block TNF- production. However, the differentiated HL-60 cells expressing lower expression of MC₁R did not show the significant effect of -MSH on the activation of p38 kinase and NFB. To our knowledge, this would appear to be the first report to show that p38 kinase is a major signaling molecule that transduces -MSH-mediated anti-inflammatory intracellular signal to the nucleus by inhibiting the NF-B activation and TNF- production.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Reagents—The anti-MC₁R antibody was obtained from Research Diagnostic Inc. (Flanders, NJ). The horseradish peroxidase-conjugated goat anti-mouse monoclonal antibody was purchased from Bio-Rad. Rabbit anti-phospho p38 kinase and anti-p38 kinase polyclonal antibody, mouse anti-phospho ERK-1/-2 monoclonal antibody, rabbit anti-phospho IB- polyclonal antibody, and horseradish peroxidase-conjugated goat anti-rabbit polyclonal antibody were purchased from Cell Signaling Technology (Beverly, MA). Rabbit anti-actin polyclonal antibody and LPS (Escherichia coli serotype O55:B5) were purchased from Sigma. p38 kinase inhibitor, PD169316, and PKA inhibitor, H-89, were purchased from Calbiochem. Rabbit polyclonal antibodies against IB-, IB kinase (IKK)-, and GST-IB- were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Protein A/G-Agarose, luciferase reporter gene assay kit, and SignaTECT PKA assay kit were purchased from Promega (Madison, WI). The -MSH antagonist, GHRP-9, and MC₃R antagonist, SHU9119, were purchased from Bachem (Bubendrof, Switzerland).

Cell Culture—HL-60 cells cultured in RPMI 1640 medium with 10% heat-inactivated fetal bovine serum were treated with 1.25% Me₂SO for 6 days to induce differentiation into neutrophils (31). THP-1 cells cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum and 1% -mercaptoethanol were treated with 150 nM PMA for 3 days to induce differentiation into macrophages (32). The differentiated neutrophils and macrophages were treated with LPS to induce TNF- production in the absence and presence of various pharmacological reagents as indicated below.

RT-PCR—Total RNA was isolated from differentiated HL-60 and THP-1 cells using the TRIzol reagent (Invitrogen), according to the manufacturer's instructions. The reverse transcription of RNA to cDNA was performed with SuperScript II⁺ reverse transcriptase (Invitrogen). TNF- primers were: forward, 5'-CAGAGGGAAGAGTCCCCCAG-3'; reverse, 5'-CCTTGGTCTGGTAGGAGACG-3'. PCR amplification consisted of 30 cycles of 94 °C for 30 s; 58 °C for 1 min; 72 °C for 30 s. MC₁R primers were: forward, 5'-CTTCTTCCTGGCTATGCTGG-3'; reverse, 5'-TCACCAGGAGCATGTCAGCA-3'. MC₃R primers were: forward, 5'-GCGACTACCTGACCTTCGAG-3'; reverse, 5'-CATGCATGAGTGTTGCTGTG-3'. MC₅R primers were: forward, 5'-TGATAGCAGACGCCTTGTG-3'; reverse, 5'-TTCTGAGGGCAAGAAAGCAT-3'. PCR amplification consisted of 30 cycles of 94 °C for 45 s; 56 °C for 45 s; and 72 °C for 45 s. Human -actin primers (positive control) were: forward, 5'-ATGTTTGAGACCTTCAACAC-3'; reverse, 5'-CAGGTCACACTTCATGATGC-3'. PCR amplification consisted of 30 cycles of 94 °C for 45 s; 56 °C for 45 s; and 72 °C for 45 s.

Western Blot Analysis—Differentiated HL-60 and THP-1 cells were lysed in a buffer containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 1.0% SDS, 1 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM leupeptin, and 1 mM phenylmethylsulfonyl fluoride in phosphate-buffered saline (pH 7.4). Equivalent amounts of protein (30 µg) were size-fractionated in a 12% SDS-polyacrylamide gel and then transferred onto a nitrocellulose membrane. The membrane was blocked with 5% skim milk in Tris-buffered saline/Tween-20 (0.05%) and blotted with the appropriate antibodies. The blots were developed using a peroxidase-conjugated secondary antibody and chemiluminescence using an ECL kit (Amersham Biosciences).

NFB Luciferase Assay—NFB activity was also directly determined by reporter gene assay. Briefly, differentiated THP-1 cells were electroporated with a plasmid containing a luciferase gene and three tandem serum response element repeats or a control vector. The transfected cells were cultured in complete medium for 24 h and untreated or treated with various pharmacological reagents as indicated in each experiment, and luciferase activity was determined by using a luciferase reporter gene assay kit from promega (Madison, WI). Luciferase activity was normalized against -galactosidase activity.

Immunoprecipitation Assay—Total cell lysates were prepared in lysis buffer containing 20 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM -glycerol phosphate, and protease inhibitors (1 mM leupeptin, 1 mM pepstatin A, and 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride) and phosphatase inhibitors (1 mM NaF and 1 mM Na₃VO₄). The cell lysates were precipitated with antibody against IKK-. Immune complexes were collected using protein A/G-agarose beads.

Kinase Assay for IKK and PKA—Differentiated THP-1 cells were lysed, and IKK was immunoprecipitated as described above. IKK activity was determined by resuspending immune complexes in 20 µl of kinase reaction buffer (50 mM HEPES, pH 7.4, 1 mM EDTA, 0.01% Brij 35, 0.1 mg/ml, 0.1% -mercaptoethanol, 0.15 M NaCl) and conducting kinase reactions for 30 min at 30 °C by adding 10 µCi/µl[-³²P]ATP and 1 µg of bacterially expressed GST-IB- as a substrate. The reaction mixtures were separated by SDS-PAGE, and radiolabeled proteins were visualized by autoradiography. PKA activity was determined by measuring the transfer of [³²P]-labeled phosphates to a phosphocellulose filter-bound peptide substrate using the SignaTECT PKA assay kit. Briefly, the kinase reaction was initiated by adding 25 µg of proteins with 100 µM biotinylated Kemptide (LRRASLG) to 25 µl of reaction mixture. After incubation at 30 °C for 5 min, the reaction was terminated by adding 12.5 µl of 7.5 M guanidine hydrochloride. An aliquot of the reaction mixture was spotted to a phosphocellulose filter, and PKA activity was measured using an LS 6000TA liquid scintillation counter.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
-MSH Inhibits LPS-induced TNF- Production in THP-1 Cells—We first investigated -MSH receptor (MC₁R) expression levels in Me₂SO-treated HL-60 and PMA-treated THP-1 cells, i.e. cells that had been caused to differentiate into macrophages and neutrophils, respectively. RT-PCR using primers specific to MC₁R mRNA yielded the expected 495-bp product. The mRNA expression levels of MC₁R in differentiated THP-1 cells were significantly higher than those in differentiated HL-60 cells (Fig. 1A). The expression levels of MC₁R protein determined by Western blot analysis also indicated that PMA-treated THP-1 cells expressed significantly more MC₁R than did Me₂SO-treated HL-60 cells (Fig. 1B). Consistent with the observations by others (25, 33), LPS treatment caused TNF- production in both PMA-treated THP-1 cells and Me₂SO-treated HL-60 cells. To examine the role of -MSH in LPS-induced TNF- production, we incubated cells with -MSH for 24 h prior to stimulation with LPS. As shown in Fig. 1C, -MSH treatment significantly reduced LPS-induced TNF- production in PMA-treated THP-1 cells. However, -MSH did not significantly affect LPS-induced TNF- production in Me₂SO-treated HL-60 cells (Fig. 1C), suggesting that the ability of -MSH to block LPS-induced TNF- production is dependent on the levels of its receptor expression.

View larger version (44K): [in this window] [in a new window]   FIG. 1. -MSH inhibits LPS-induced TNF- production in THP-1 cells. Total RNA was isolated from PMA-treated THP-1 cells and Me2SO-treated HL-60 cells, and MC1R mRNA transcript levels were determined by RT-PCR (A). M.W., molecular weight. MC1R protein levels in PMA-treated THP-1 cells and Me2SO-treated HL-60 cells were determined by Western blot analysis (B). PMA-treated THP-1 cells and Me2SO-treated HL-60 cells were untreated or treated with -MSH (50 nM) for 24 h and then stimulated with LPS (10 ng/ml) for 1 h. mRNA transcript levels for MC1R and -actin were determined by RT-PCR (C). The data represent a typical result from at least four independent experiments.

-MSH Blocks LPS-induced TNF- Production by Inhibiting p38 Kinase Signaling—LPS is known to stimulate TNF- production in monocytes and macrophages by activating MAP kinase signaling (21, 27, 34). Therefore, we next examined whether -MSH inhibits LPS-induced TNF- production by modulating LPS-induced p38 kinase activation. As expected, Western blot analysis showed that LPS treatment activated p38 kinase in both differentiated THP-1 cells and HL-60 cells (Fig. 2A). Treatment of cells with -MSH (50 nM) prior to LPS stimulation significantly reduced the amount of activated p38 kinase in PMA-treated THP-1 cells but not in Me₂SO-treated HL-60 cells (Fig. 2B). This suggests that the ability of -MSH to block LPS-induced p38 kinase activity is proportional to the levels of its receptor expression, which is consistent with the previous set of experimental results. We further confirmed the significance of the inhibition of LPS-induced p38 kinase activation by -MSH in TNF- production by a p38 inhibitor. As shown in Fig. 3, -MSH inhibited LPS-induced p38 kinase activation (Fig. 3A) and TNF--production (Fig. 3C) in PMA-treated THP-1 cells in a dose-dependent manner. In addition, direct inhibition of LPS-induced p38 kinase activation with specific inhibitor PD169316 also blocked LPS-induced p38 kinase activation (Fig. 3A) and TNF- production (Fig. 3D) in a dose-dependent manner. The results from multiple Western blots were scanned and quantified. The densitometric analysis indicated that the phospho-p38 kinase levels were reduced to 27–31% and 25–28% of the control level (treated with LPS only) by 50 nM -MSH and 2 µM PD169316 (Fig. 3B). The results suggest that the inhibition of p38 kinase by -MSH contributes to the inhibition of LPS-induced TNF- production in PMA-treated THP-1 cells.

View larger version (31K): [in this window] [in a new window]   FIG. 2. -MSH inhibits LPS-induced p38 kinase activation. PMA-treated THP-1 cells and Me2SO-treated HL-60 cells were stimulated with LPS (10 ng/ml) for the indicated time periods (0–60 min), and the amounts of total p38 kinase (p38) and phosphorylated p38 kinase (pp38) were determined by Western blot analysis (A). The cells were untreated or treated with -MSH (50 nM) for 24 h and then left untreated or stimulated with LPS (10 ng/ml) for 1 h. The amounts of p38 and pp38 were determined by Western blot analysis (B). The data represent a typical result from three independent experiments.

View larger version (33K): [in this window] [in a new window]   FIG. 3. Inhibition of LPS-stimulated p38 kinase activation by -MSH causes the blockade of TNF- production. PMA-treated THP-1 cells were pretreated with the indicated concentrations of -MSH for 24 h (upper panel) or PD169316 for 30 min (lower panel) and then stimulated with LPS (10 ng/ml) for 1 h. Expression levels of p38 and phosphorylated p38 kinase (pp38) were determined by Western blot analysis (A). Blots of pp38 in A were scanned, and the band intensities were quantitated. The band intensity values were used to determine the relative amount of pp38. The relative value of pp38 protein is expressed as the percentage of that in the presence of LPS only; *,p < 0.05; **, p < 0.01 versus the value in the presence of LPS only (B). Transcript levels for TNF- and -actin were determined by RT-PCR in PMA-treated THP-1 cells pretreated with the indicated concentrations of -MSH for 24 h (C) or PD169316 for 30 min (D) and then stimulated with LPS (10 ng/ml) for 1 h. The data represent a typical result from four independent experiments. M.W., molecular weight.

-MSH Inhibits LPS-induced NFB Activation via p38 Kinase Signaling—Because -MSH is known to inhibit activation of NFB (13, 14), we next investigated whether -MSH inhibits LPS-induced NFB activation and whether there is a functional relationship between p38 kinase and NFB activation. NFB activation was determined by examining phosphorylation of IB because degradation of IB via its phosphorylation is necessary for nuclear translocation of NFB and subsequent activation of target gene expression. In PMA-treated THP-1 cells, LPS treatment caused activation of NFB as demonstrated by the measures of IB phosphorylation (Fig. 4A, upper panel) and NFB reporter gene assay (Fig. 4C). As expected, the level of the IB protein decreased as the phosphorylation level of the IB protein increased (Fig. 4A, upper panel). Pretreatment of -MSH that inhibits LPS-induced p38 kinase activation or direct inhibition of p38 kinase with PD169316 blocked LPS-induced IB phosphorylation and LPS-induced IB degradation (Fig. 4A, middle and lower panels) and transcriptional activity of NFB (Fig. 4C), suggesting that inhibition of LPS-induced p38 kinase activation by -MSH is responsible for the inhibition of NFB. The phospho-IB levels were reduced to 22–28 and 26–33% of the control level (treated with LPS only) by 50 nM -MSH and 2 µM PD169316, respectively (Fig. 4B). The ability of -MSH to inhibit IB- phosphorylation appears related to its ability to inhibit IKK as -MSH inhibits the LPS-induced IKK activity (Fig. 4D). In contrast to the inhibition of NFB by the blockade of p38 kinase activation, inhibition of NFB activation by treatment with SN50 peptide, which blocks NFB activation by inhibiting nuclear translocation of NFB (35, 36), did not affect p38 kinase activation (Fig. 5A) but did inhibit LPS-induced TNF- production (Fig. 5B). Taken together, these results suggest that LPS-induced p38 kinase activation is necessary for NFB activation and that -MSH inhibits TNF- production by blocking LPS-induced p38 kinase activation and subsequent NFB activation.

View larger version (39K): [in this window] [in a new window]   FIG. 4. -MSH blocks LPS-induced NFB activation by inhibition of p38 kinase. PMA-treated THP-1 cells were stimulated with LPS (10 ng/ml) for the indicated time periods (upper panel). Alternatively, THP-1 cells were pretreated with the indicated concentrations of -MSH (middle panel) for 24 h or PD169316 for 30 min (lower panel) and then stimulated with LPS (10 ng/ml) for 1 h. Expression levels of IB- and phosphorylated IB- (pIB-) were determined by Western blot analysis (A). Blots of pIB- in A were scanned, and the band intensities were quantitated. The band intensity values were used to determine the relative amount of pIB-. The relative value of pIB- protein is expressed as percentage of that in the presence of LPS only, *, p < 0.05; **, p < 0.01 versus the value in the presence of LPS only (B). PMA-treated THP-1 cells were untreated or treated with -MSH (50 nM) for 24 h or PD169316 (2 µM) for 30 min and then stimulated with LPS (10 ng/ml) for 1 h. NFB activity was determined by luciferase assay (C). THP-1 cells were untreated or treated with -MSH (50 nM) for 24 h and then stimulated with LPS (10 ng/ml) for 1 h. IKK kinase assays were performed using GST-IB- as a substrate (D). The data represent results of a typical experiments (A and D) and mean values with standard deviation (B) (n = 4).

View larger version (35K): [in this window] [in a new window]   FIG. 5. -MSH blocks TNF- production by inhibiting NFB activation. PMA-treated THP-1 cells were untreated or treated with -MSH (50 nM) for 24 h or with SN-50 peptide (50 nM) for 30 min and then stimulated with LPS (10 ng/ml) for 1 h. Expression levels of p38 and phosphorylated p38 kinase (pp38) were determined by Western blot analysis (A). Transcript levels for TNF- and -actin were determined by RT-PCR (B). The data represent a typical result from four independent experiments. M.W., molecular weight.

It was found that the PMA-treated THP-1 cells also expressed MC₃R and MC₅R, in addition to the MC₁R receptor, whereas the Me₂SO-treated HL-60 cells only expressed the MC₁R receptor (Fig. 6A). As such, this finding is consistent with the recent report by Taherzadeh et al. (19), who found that THP-1 cells express MC₁R, MC₃R, and MC₅R. Since MC₁R and MC₃R, and yet not MC₅R, are known to be associated with the anti-inflammatory effect of -MSH (15, 30), plus the expression level of MC₅R in THP-1 cells and MC₅R affinity to -MSH are much lower than those for MC₁R and MC₃R (37), the receptor specificity was investigated using GHRP-6, which is a non-selective antagonist of -MSH receptors, and SHU9119, which is a specific antagonist of MC₃R. When the differentiated THP-1 cells were pretreated with GHRP-6, the inhibitory effects of -MSH on LPS-induced p38 kinase activation (Fig. 6B) and IB- phosphorylation (Fig. 6C) were completely abrogated, whereas MC₃R-specific SHU9119 had no impact on the effects of -MSH (Fig. 6, B and C). Accordingly, these findings support the conclusion that MC₁R is the major -MSH receptor that mediates the inhibitory effect of -MSH on the LPS-induced activation of p38 kinase and NFB, leading to a reduced TNF- production in differentiated THP-1 cells.

View larger version (40K): [in this window] [in a new window]   FIG. 6. An -MSH antagonist abrogates the inhibitory effects of -MSH on LPS-induced activation of p38 kinase and NFB. Total RNA was isolated from PMA-treated THP-1 cells and Me2SO-treated HL-60 cells, and mRNA levels of MC3R and MC5R were determined by RT-PCR (A). M.W., molecular weight. PMA-treated THP-1 cells were pretreated with -MSH (50 nM), non-selective antagonist GHRP-9 (50 nM), or MC3R antagonist SHU9119 (50 nM) for 24 h or PD169316 (2 µM) for 30 min, and then the cells were stimulated with LPS (10 ng/ml) for 1 h. Western blot analysis was performed to determine the expression levels of p38 and phosphorylated p38 kinase (pp38) (B) and phosphorylated IB and IB (C). The data represent a typical result from three independent experiments.

Activation of PKA Is Required for the Inhibitory Effects of -MSH on p38 Kinase and NFB—Because -MSH binding to MC₁R is known to activate the PKA signaling pathway (15, 19, 20), we also examined the functional relationship between PKA activation and -MSH inhibition of p38 kinase and NFB. As expected, -MSH stimulated PKA activity in PMA-treated THP-1 cells. The addition of LPS alone did not significantly affect PKA activation, whereas addition of the PKA-specific inhibitor H-89 dramatically blocked -MSH-induced PKA activation (Fig. 7A). The inhibition of -MSH-induced PKA activation by H-89 treatment blocked the inhibition of LPS-induced activation of p38 kinase, IB phosphorylation, and IB degradation (Fig. 7B) as well as TNF- production (Fig. 7C). These results clearly indicate that stimulation of PKA by -MSH causes inhibition of LPS-induced activation of p38 kinase and subsequent NFB activation to block TNF- production.

View larger version (23K): [in this window] [in a new window]   FIG. 7. Activation of PKA is required for the inhibition p38 kinase and NFBby -MSH. PMA-treated THP-1 cells were pretreated with -MSH (50 nM) with or without PKA inhibitor H-89 (10 µM) for 2 h, and then the cells were stimulated with LPS (10 ng/ml) for 1 h before PKA activity was determined. *, p < 0.05; ***, p < 0.001 versus the value of control (A). Levels of p38, phosphorylated p38 kinase (pp38), phosphorylated IB- (pIB-), and IB were determined by Western blot analysis (B). Transcript levels of TNF- and -actin were determined by RT-PCR (C). The data represent mean values with standard deviation (A) and results of typical experiments from four independent experiments.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
-MSH is known to suppress inflammation by inhibiting expression of inflammatory cytokines, including TNF- in leukocytes by inhibiting NF-B activation (38). However, the molecular mechanisms of these -MSH anti-inflammatory effects have not been defined previously. MC₁R is constitutively expressed in monocytes and subpopulations of lymphocytes and plays an important role in the anti-inflammatory action of -MSH (19, 39). Here, we found that PMA-treated THP-1 cells express significantly more MC₁R when compared with Me₂SO-treated HL-60 cells. By using differentiated THP-1 (high MC₁R cells) and HL-60 (low MC₁R cells), we demonstrated that -MSH blocks LPS-induced TNF- production by inhibiting LPS-induced activation of p38 kinase and subsequent NFB activation in a manner dependent on MC₁R expression. We also demonstrated that the inhibitory effects of -MSH require MC₁R-mediated activation of PKA. Since MC₁R and MC₃R are known to be associated with the anti-inflammatory effect of -MSH (15, 30) and PMA-treated THP-1 cells express MC₃R, we checked the effects of -MSH antagonists, GHRP-6 (a non-selective antagonist of -MSH receptors) and SHU9119 (an antagonist of MC₃R), on the activation of p38 kinase and the phosphorylation of IB. We found that the anti-inflammatory effects of -MSH were observed only in high MC₁R cells and that these effects were completely abolished by the addition of GHRP-6 but not by that of SHU9119 (Fig. 6). These observations also suggest that MC₁R expression is required for the inhibitory action of -MSH in differentiated THP-1 cells. Studies using cultured human astrocytes, whole murine brain, and human monocyte/macrophages have indicated that a primary effect of -MSH is modulation of activation of NFB (38). Consistent with this is our observation that the ability of -MSH to inhibit TNF- production is due to the blockade of LPS-induced NFB activation. The ability of -MSH to inhibit NFB activation appears to be indirect in that it involves inhibition of IKK activity. This is based on the observation that -MSH inhibits LPS-induced IKK activity, leading to decreased IB- phosphorylation (Fig. 4). We also observed that -MSH inhibits TNF--induced IB phosphorylation and NFB activation (data not shown), as has already been reported by Manna et al. (40).

We also found that the inhibition of NFB by -MSH is due to inhibition of the upstream signaling molecule p38 kinase. This is consistent with observations by others indicating that LPS stimulates p38 kinase in various cell types (41, 42) and that p38 kinase activation by various extracellular stimuli leads to the activation of NFB (43, 44). Experimentally, we found that the optimal -MSH concentration for inhibition of p38 kinase activation and subsequent NFB activation under our experimental conditions was 50 nM. Indeed, we found that higher concentrations of -MSH were less effective in attenuating p38 kinase activation (Fig. 3A). This biphasic inhibitory effect of -MSH on p38 kinase is consistent with the previous observation that -MSH is most effective at a nanomolar concentration and that its anti-inflammatory effects are biphasic in terms of concentration (20, 45).

Stimulation of MC₁R activates adenyl cyclase, leading to the production of cAMP and subsequent activation of PKA (15, 19, 20). Our results indicate that the inhibitory effects of -MSH on LPS-induced activation of p38 kinase and NFB are mediated by the activation of PKA via the stimulation of the MC₁R receptor. This is based on the observation that inhibition of PKA with H-89 blocks the inhibitory effects of -MSH on the inhibition of p38 kinase activation and TNF- production (Fig. 7). Negative control of PKA on NFB activation has been reported previously (46), and this result, in combination with our findings, suggests that it would be interesting to elucidate the mechanisms leading to the inhibition of p38 kinase by the activation of PKA. One possibility is that the inhibition is mediated through inhibition of Raf-1 by PKA (47) because Raf-1 is reported to induce the activation of NFB through MAP kinase kinase kinase (MEKK)-1, which induces MAP kinase kinase (MEK)-3/-6 and p38 kinase activation (44, 48).

Recently, Mandrika et al. (30) reported that inhibition of PKA by H-89 blocks the inhibitory effects of -MSH on LPS/interferon--induced nitric oxide production and NFB activation measured by NFB-dependent reporter assay but that it does not affect NFB translocation to the nucleus in RAW 264.7 mouse macrophage. This group suggested that -MSH acts via two mechanisms: one cAMP-independent and the other dependent on MC₁R/cAMP activation. In this study, we demonstrated that PKA activity is required for the blockade of LPS-induced activation of p38 kinase and subsequent NFB activation and TNF- production. Thus the -MSH inhibition of p38 kinase activation in LPS-stimulated THP-1 occurs through a MC₁R/cAMP-dependent mechanism.

The current work demonstrated that the LPS-induced activation of p38 kinase was decreased by -MSH treatment and that the IKK activity was subsequently down-regulated, thereby leading to a decrease in the phosphorylation and degradation of IB and the inhibition of NFB activation. It was reported that p38 kinase inhibitors could be used for the therapeutic drug for cytokine-mediated diseases (26). Because our results showed that the down-regulated p38 kinase in LPS-induced monocytes treated with -MSH or the p38 kinase inhibitor PD169316 induces the inhibition of IKK, NFB activation, and TNF- production, the application of -MSH as a therapeutic drug for inflammatory diseases by acting as a p38 kinase inhibitor should be attempted.

	FOOTNOTES

 
^* This work was supported by Grants KGM1000111 and KGS1010212 from the Korea Research Institute of Bioscience and Biotechnology. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 82-42-860-4157; Fax: 82-42-860-4593; E-mail: haryoung{at}mail.kribb.re.kr.

¹ The abbreviations used are: -MSH, -melanocyte-stimulating hormone; ERK, extracellular signal-regulated protein kinase; IB, inhibitory B; IKK, IB kinase; LPS, lipopolysaccharide; MAP, mitogen-activated protein; MAPK, MAP kinase; MEK, MAPK/ERK kinase; MEKK, MEK kinase; MCR, melanocortin receptors; NFB, nuclear factor B; PKA, protein kinase A; PMA, phorbol myristate acetate; TNF-, tumor necrosis factor-.

	ACKNOWLEDGMENTS

 
We thank Michael Melinick (Cell Signaling Technology, Beverly, MA) for the anti-phospho MAPK antibodies and Hyunmi Pyo (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea) for technical assistance.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Catania, A., and Lipton, J. M. (1994) Neuroimmunomodulation 1, 93–99[CrossRef][Medline] [Order article via Infotrieve]
2. Chambers, D. A., and Schauenstein, K. (2000) Immunol. Today 21, 168–170[CrossRef][Medline] [Order article via Infotrieve]
3. Catania, A., and Lipton, J. M. (1993) Ann. N. Y. Acad. Sci. 680, 412–423[Medline] [Order article via Infotrieve]
4. Catania, A., Gerloni, V., Procaccia, S., Airaghi, L., Manfredi, M. G., Lomater, C., Grossi, L., and Lipton, J. M. (1994) Neuroimmunomodulation 1, 321–328[Medline] [Order article via Infotrieve]
5. Lipton, J. M., and Catania, A. (1998) Ann. N. Y. Acad. Sci. 840, 373–380[Abstract/Free Full Text]
6. Ichiyama, T., Sakai, T., Catania, A., Barsh, G. S., Furukawa, S., and Lipton, J. M. (1999) J. Neuroimmunol. 99, 211–217[CrossRef][Medline] [Order article via Infotrieve]
7. Chiao, H., Foster, S., Thomas, R., Lipton, J., and Star, R. A. (1996) J. Clin. Invest. 97, 2038–2044[Medline] [Order article via Infotrieve]
8. Oktar, B. K., Ercan, F., Yegen, B. C., and Alican, I. (2000) Peptides (Elmsford) 21, 1271–1277[CrossRef][Medline] [Order article via Infotrieve]
9. Rajora, N., Boccoli, G., Catania, A., and Lipton, J. M. (1997) Peptides (Elmsford) 18, 381–385[CrossRef][Medline] [Order article via Infotrieve]
10. Airaghi, L., Lettino, M., Manfredi, M. G., Lipton, J. M., and Catania, A. (1995) Am. Heart J. 130, 204–211[CrossRef][Medline] [Order article via Infotrieve]
11. Cannon, J. G., Tatro, J. B., Reichlin, S., and Dinarello, C. A. (1986) J. Immunol. 137, 2232–2236[Abstract]
12. Rajora, N., Boccoli, G., Burns, D., Sharma, S., Catania, A. P., and Lipton, J. M. (1997) J. Neurosci. 17, 2181–2186[Abstract/Free Full Text]
13. Bohm, M., Schulte, U., Kalden, H., and Luger, T. A. (1999) Ann. N. Y. Acad. Sci. 885, 277–286[Abstract/Free Full Text]
14. Ichiyama, T., Zhao, H., Catania, A., Furukawa, S., and Lipton, J. M. (1999) Exp. Neurol. 157, 359–365[CrossRef][Medline] [Order article via Infotrieve]
15. Getting, S. J. (2002) Trends Pharmacol. Sci. 23, 447–449[CrossRef][Medline] [Order article via Infotrieve]
16. Rajora, N., Ceriani, G., Catania, A., Star, R. A., Murphy, M. T., and Lipton, J. M. (1996) J. Leukocyte Biol. 59, 248–253[Abstract]
17. Mountjoy, K. G., Robbins, L. S., Mortrud, M. T., and Cone, R. D. (1992) Science 257, 1248–1251[Abstract/Free Full Text]
18. Gantz, I., Konda, Y., Tashiro, T., Shimoto, Y., Miwa, H., Munzert, G., Watson, S. J., DelValle, J., and Yamada, T. (1993) J. Biol. Chem. 268, 8246–8250[Abstract/Free Full Text]
19. Taherzadeh, S., Sharma, S., Chhajlani, V., Gantz, I., Rajora, N., Demitri, M. T., Kelly, L., Zhao, H., Ichiyama, T., Catania, A., and Lipton, J. M. (1999) Am. J. Physiol. 276, R1289–R1294[Medline] [Order article via Infotrieve]
20. Catania, A., Rajora, N., Capsoni, F., Minonzio, F., Star, R. A., and Lipton, J. M. (1996) Peptides (Elmsford) 17, 675–679[CrossRef][Medline] [Order article via Infotrieve]
21. Guha, M., and Mackman, N. (2001) Cell. Signal. 13, 85–94[CrossRef][Medline] [Order article via Infotrieve]
22. Hawiger, J. (2001) Immunol. Res. 23, 99–109[CrossRef][Medline] [Order article via Infotrieve]
23. White, J. E., Lin, H. Y., Davis, F. B., Davis, P. J., and Tsan, M. F. (2000) J. Cell. Physiol. 182, 381–389[CrossRef][Medline] [Order article via Infotrieve]
24. Mancuso, G., Midiri, A., Beninati, C., Piraino, G., Valenti, A., Nicocia, G., Teti, D., Cook, J., and Teti, G. (2002) J. Immunol. 169, 1401–1409[Abstract/Free Full Text]
25. MacKenzie, S., Fernandez-Troy, N., and Espel, E. (2002) J. Leukocyte Biol. 71, 1026–1032[Abstract/Free Full Text]
26. Salituro, F. G., Germann, U. A., Wilson, K. P., Bemis, G. W., Fox, T., and Su, M. S. (1999) Curr. Med. Chem. 6, 807–823[Medline] [Order article via Infotrieve]
27. Rutault, K., Hazzalin, C. A., and Mahadevan, L. C. (2001) J. Biol. Chem. 276, 6666–6674[Abstract/Free Full Text]
28. Nick, J. A., Young, S. K., Arndt, P. G., Lieber, J. G., Suratt, B. T., Poch, K. R., Avdi, N. J., Malcolm, K. C., Taube, C., Henson, P. M., and Worthen, G. S. (2002) J. Immunol. 169, 5260–5269[Abstract/Free Full Text]
29. Luger, T. A., Brzoska, T., Scholzen, T. E., Kalden, D. H., Sunderkotter, C., Armstrong, C., and Ansel, J. (2000) Ann. N. Y. Acad. Sci. 917, 232–238[Abstract/Free Full Text]
30. Mandrika, I., Muceniece, R., and Wikberg, J. E. (2001) Biochem. Pharmacol. 61, 613–621[CrossRef][Medline] [Order article via Infotrieve]
31. Collins, S. J., Ruscetti, F. W., Gallagher, R. E., and Gallo, R. C. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 2458–2462[Abstract/Free Full Text]
32. Kurosaka, K., Watanabe, N., and Kobayashi, Y. (1998) J. Immunol. 161, 6245–6249[Abstract/Free Full Text]
33. Nagahira, A., Nagahira, K., Murafuji, H., Abe, K., Magota, K., Matsui, M., and Oikawa, S. (2001) Biochem. Biophys. Res. Commun. 281, 1030–1036[CrossRef][Medline] [Order article via Infotrieve]
34. Haddad, E. B., Birrell, M., McCluskie, K., Ling, A., Webber, S. E., Foster, M. L., and Belvisi, M. G. (2001) Br. J. Pharmacol. 132, 1715–1724[CrossRef][Medline] [Order article via Infotrieve]
35. Uzzo, R. G., Dulin, N., Bloom, T., Bukowski, R., Finke, J. H., and Kolenko, V. (2001) Biochem. Biophys. Res. Commun. 287, 895–899[CrossRef][Medline] [Order article via Infotrieve]
36. Yan, X., Wu Xiao, C., Sun, M., Tsang, B. K., and Gibb, W. (2002) Biol. Reprod. 66, 1667–1671[Abstract/Free Full Text]
37. Wikberg, J. E., Muceniece, R., Mandrika, I., Prusis, P., Lindblom, J., Post, C., and Skottner, A. (2000) Pharmacol. Res. 42, 393–420[CrossRef][Medline] [Order article via Infotrieve]
38. Lipton, J. M., Zhao, H., Ichiyama, T., Barsh, G. S., and Catania, A. (1999) Ann. N. Y. Acad. Sci. 885, 173–182[Abstract/Free Full Text]
39. Neumann Andersen, G., Nagaeva, O., Mandrika, I., Petrovska, R., Muceniece, R., Mincheva-Nilsson, L., and Wikberg, J. E. (2001) Clin. Exp. Immunol. 126, 441–446[CrossRef][Medline] [Order article via Infotrieve]
40. Manna, S. K., and Aggarwal, B. B. (1998) J. Immunol. 161, 2873–2880[Abstract/Free Full Text]
41. Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J., and Chen, Z. J. (2001) Nature 412, 346–351[CrossRef][Medline] [Order article via Infotrieve]
42. Shuto, T., Xu, H., Wang, B., Han, J., Kai, H., Gu, X. X., Murphy, T. F., Lim, D. J., and Li, J. D. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 8774–8779[Abstract/Free Full Text]
43. Chen, C. C., and Wang, J. K. (1999) Mol. Pharmacol. 55, 481–488[Abstract/Free Full Text]
44. Wang, D., and Richmond, A. (2001) J. Biol. Chem. 276, 3650–3659[Abstract/Free Full Text]
45. Haycock, J. W., Rowe, S. J., Cartledge, S., Wyatt, A., Ghanem, G., Morandini, R., Rennie, I. G., and MacNeil, S. (2000) J. Biol. Chem. 275, 15629–15636[Abstract/Free Full Text]
46. Zhong, H., SuYang, H., Erdjument-Bromage, H., Tempst, P., and Ghosh, S. (1997) Cell 89, 413–424[CrossRef][Medline] [Order article via Infotrieve]
47. Dhillon, A. S., Pollock, C., Steen, H., Shaw, P. E., Mischak, H., and Kolch, W. (2002) Mol. Cell. Biol. 22, 3237–3246[Abstract/Free Full Text]
48. Baumann, B., Weber, C. K., Troppmair, J., Whiteside, S., Israel, A., Rapp, U. R., and Wirth, T. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4615–4620[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				D. Li and A. W. Taylor Diminishment of {alpha}-MSH anti-inflammatory activity in MC1r siRNA-transfected RAW264.7 macrophages J. Leukoc. Biol., July 1, 2008; 84(1): 191 - 198. [Abstract] [Full Text] [PDF]